Acute coronary syndrome, acute myocardial infarction.
Massive deep vein thrombosis with the risk of gangrene.
Acute, subacute and chronic thrombosis of peripheral arteries with the threat of ischemia.
Thrombosis of the central artery or central retinal vein.
Streptocinaza (streptokinase) lyophilizate for solution for infusion 1 500 000 IU №1 vial
active ingredient: streptokinase; 1 bottle contains streptokinase 750,000 IU or 1,500,000 IU
excipients: human albumin 20%, polygelin (gemasel).
Lyophilizate for solution for infusion.
Antithrombotic agents. Enzymes.
ATC code B01A D01.
It is prescribed for the treatment of embolism (blockage) of the pulmonary artery and its branches. Treatment of thrombosis (formation of a blood clot in a vessel) of arteries, blockage (embolism) of peripheral arteries, vein thrombosis (both deep and close to the skin). Effective in the treatment of acute myocardial infarction in the first 12 hours, blockage of the vessels of the mesh.
Able to activate the fibrinolytic (that is, able to dissolve blood clots) enzyme system, to break down fibrin, which is contained in blood clots, thereby dissolving the blood clot that clogged the vessel (thrombolysis phenomenon).
It is forbidden to use for hemorrhagic diathesis, fresh bleeding, high and pressure, streptococcal sepsis, stomach ulcers, septic endocarditis, severe diabetes mellitus. It should be carefully prescribed for severe liver and kidney damage, tuberculosis in the active phase.
Application during pregnancy and lactation
Do not use in the first 18 weeks of pregnancy and with poor blood clotting in women.
Method of administration and dosage
The drug Streptocinaza lyophilizate for solution , vials of 750,000 IU, is administered intravenously or intraarterially.
The drug Streptocinaza lyophilizate for solution , bottles of 1500000 IU, is prescribed intravenously or intracoronary.
At the beginning of therapy, a concentrated solution of Streptokinase-Biopharma is prepared: slowly introduce 5 ml of a sterile 0.9% solution of NaCl (sodium chloride) into the vial and mix gently by rotating the vial. Do not add any other medicines to the vial. To prepare an infusion solution, add the required amount of a concentrated solution to 50-200 ml of sterile 0.9% sodium chloride solution or Ringer’s solution, or 5% glucose solution.
Dosing Streptocinaza lyophilizate for solution
Acute ST-segment elevation myocardial infarction. The dose is 1500000 MO intravenously over 1:00.
The introduction of the drug intracoronary is carried out according to the scheme: 20,000 IU of Streptocinaza lyophilizate for solution bolus; in the future, maintenance fibrinolytic therapy is carried out by administering the drug at a dose of 2000 – 4000 IU / min for 0.5 – 1.5 hours (depending on the rate of recovery of the patency of the coronary artery). After completion of the administration of streptokinase-Biopharma, it is recommended to prescribe acetylsalicylic acid (150 mg/day, per os) as soon as possible.
Deep vein thrombosis. The initial dose is 250,000 IU, which is administered intravenously for 0.5 hours, then a maintenance dose of 100,000 IU / h is administered. The duration of treatment is 72 hours.
Pulmonary embolism. For short-term thrombolysis, Streptokinase-Biopharma is administered intravenously at a dose of 1,500,000 IU over 1-2 hours.
Standard input mode: initial dose of 250,000 IU, which is administered over 0.5 hour; maintenance dose – 100,000 IU / h. Duration of treatment – 24 hours.
Thrombosis of peripheral arteries. Streptokinase-Biopharma is used intra-arterially through a local intra-arterial catheter according to the following scheme: staged infusions – from 1000 to 2500 IU with an interval of 3-5 minutes, the maximum duration of administration is 10:00. The total maximum dose is 250,000 IU.
In the presence of multiple occlusion, the initial dose of Streptokinase-Biopharma is 250,000 IU, which is administered for 0.5 hours, then the maintenance dose of 100,000 IU / h is continued. The duration of treatment is up to 5 days.
Thrombosis of the central vessels of the retina. The initial dose is 250,000 IU, which is administered intravenously over 0.5 hours. In the future, a maintenance dose of 100,000 IU / h is administered. The duration of treatment is 12:00.
Unlikely. Can theoretically cause a decrease in the patient’s blood clotting.
An unusual reaction to protein may occur: nausea, chills, bruising. To prevent such reactions, it is recommended to administer prednisolone (50 mg).